1.29

15.18% 0.17

After Hours: 1.25 -0.04 -3.10%

Actinium Pharmaceuticals Inc (ATNM)

Overview News Price History Option Chain Discussions Forecast Stock Split

Actinium Pharmaceuticals Inc stock is traded at $1.29, with a volume of 929.13K. It is up +15.18% in the last 24 hours and down -7.19% over the past month. Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Previous Close:

$1.12

Open:

$1.14

24h Volume:

929.13K

Relative Volume:

3.11

Market Cap:

$40.24M

Revenue:

$1.05M

Net Income/Loss:

$-48.82M

P/E Ratio:

-0.7088

EPS:

-1.82

Net Cash Flow:

$-47.49M

1W Performance:

+4.88%

1M Performance:

-7.19%

6M Performance:

-82.91%

1Y Performance:

-72.26%

1-Day Range:

$1.125

$1.29

1-Week Range:

$1.10

$1.29

52-Week Range:

$1.10

$10.24

Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile

Name

Actinium Pharmaceuticals Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

646-767-3870

Address

275 Madison Avenue, 7th Floor, New York, NY

Employee

Twitter

@actiniumpharma

Next Earnings Date

2024-12-11

Latest SEC Filings

ATNM's Discussions on Twitter

Compare ATNM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATNM Actinium Pharmaceuticals Inc	1.29	40.24M	1.05M	-48.82M	-47.49M	-1.83
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-07-24	Downgrade	B. Riley Securities	Buy → Neutral
May-14-24	Initiated	Stephens	Overweight
Sep-06-23	Initiated	HSBC Securities	Buy
Feb-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-08-22	Initiated	Cantor Fitzgerald	Overweight
Aug-25-22	Initiated	B. Riley Securities	Buy
Nov-05-20	Initiated	Alliance Global Partners	Buy
Dec-06-17	Initiated	B. Riley FBR, Inc.	Buy
Oct-23-17	Resumed	ROTH Capital	Buy
Sep-14-17	Initiated	Maxim Group	Buy
Aug-25-16	Initiated	ROTH Capital	Buy
Feb-29-16	Initiated	H.C. Wainwright	Buy
Oct-15-15	Initiated	FBR Capital	Outperform
Oct-01-14	Initiated	MLV & Co	Buy
Jul-22-14	Initiated	Canaccord Genuity	Buy

View All

Actinium Pharmaceuticals Inc Stock (ATNM) Latest News

Dec 20, 2024

Charles Schwab Investment Management Inc. Has $136,000 Stock Position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World

Dec 20, 2024

Dec 16, 2024

Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials - GlobeNewswire Inc.

Dec 16, 2024

Dec 14, 2024

ATNM stock touches 52-week low at $1.17 amid market challenges - Investing.com Australia

Dec 14, 2024

Dec 11, 2024

My Top 2 Stock Picks For A 2025 Rebound - Seeking Alpha

Dec 11, 2024

Dec 07, 2024

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Dec 07, 2024

Nov 27, 2024

Actinium Pharmaceuticals 2024 Stockholder Meeting Outcomes - TipRanks

Nov 27, 2024

Nov 21, 2024

Stephens Reaffirms “Overweight” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World

Nov 21, 2024

Nov 18, 2024

Actinium Pharmaceuticals Continues R&D Focus Amid Financial Progress - TipRanks

Nov 18, 2024

Actinium Pharma keeps stock target with Buy rating on Q3 earnings - Investing.com UK

Nov 18, 2024

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 - PR Newswire

Nov 18, 2024

Nov 17, 2024

HC Wainwright Reaffirms “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World

Nov 17, 2024

Nov 15, 2024

Actinium: Q3 Earnings Snapshot - mySA

Nov 15, 2024

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $11.40 Consensus Price Target from Analysts - Defense World

Nov 15, 2024

Nov 14, 2024